scholarly journals G1/S-specific Cyclin-D1 Might be a Prognostic Biomarker for Patients with Laryngeal Squamous Cell Carcinoma

2012 ◽  
Vol 13 (5) ◽  
pp. 2133-2137 ◽  
Author(s):  
Ying-Yao Zhang ◽  
Zhi-Na Xu ◽  
Jun-Xi Wang ◽  
Dong-Min Wei ◽  
Xin-Liang Pan
2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Zhisen Shen ◽  
Chongchang Zhou ◽  
Jinyun Li ◽  
Dong Ye ◽  
Hongxia Deng ◽  
...  

The purpose of this study was to evaluate the contribution ofSHISA3promoter methylation to laryngeal squamous cell carcinoma (LSCC).SHISA3promoter methylation status and expression were determined using methylation-specific polymerase chain reaction (MSP) and quantitative real-time PCR (qRT-PCR) in 93 paired LSCC and adjacent normal tissues, respectively. Furthermore, the regulatory function of theSHISA3promoter fragment was analyzed using a luciferase reporter assay. The results reveal that there is a significant increase inSHISA3methylation in LSCC tissues compared with corresponding nontumor tissuesP=4.58E-12. The qRT-PCR results show a significant association betweenSHISA3methylation and expression in LSCCP=1.67E-03. In addition, the area under the receiver operating characteristic curve was 0.91. Consequently, a log-rank test and multivariate Cox analysis suggest thatSHISA3promoter hypermethylation is a predictor of poor overall survival for LSCC (log-rankP= 0.024; HR = 2.71; 95% CI = 1.024–7.177;P= 0.047). The results indicate thatSHISA3promoter hypermethylation might increase the risk of LSCC through regulation of gene expression and is a potential diagnostic and prognostic biomarker for LSCC.


2020 ◽  
Vol 21 (2) ◽  
pp. 379-384
Author(s):  
Efthymios Kyrodimos ◽  
Vasileios Papanikolaou ◽  
Evangelos Tsiambas ◽  
Dimitrios Kikidis ◽  
Dimitrios Peschos ◽  
...  

2020 ◽  
Vol 15 (3) ◽  
pp. 245-250
Author(s):  
Vahid Zand ◽  
Fariba Binesh ◽  
Mojtaba Meybodian ◽  
Farzan Safi Dahaj ◽  
Arezoo Alamdar yazdi

2020 ◽  
Vol 48 (4) ◽  
pp. 030006052091925
Author(s):  
Jun Ge ◽  
Li Jiang ◽  
Yuke Tian ◽  
Min Zheng ◽  
Meiling Huang ◽  
...  

Objectives This study aimed to explore the expression profile of the Forkhead box protein L2 gene ( FOXL2) and to determine its prognostic value and associated epigenetic and genetic alterations in patients with laryngeal squamous cell carcinoma (LSCC). Materials and methods Data for a subset of patients with LSCC (N = 116) were extracted from the head and neck squamous cell carcinoma dataset of The Cancer Genome Atlas and analyzed in relation to FOXL2 expression and survival. Results Aberrant FOXL2 expression was an independent prognostic factor for progression-free survival (PFS) (hazard ratio (HR): 2.63, 95% confidence interval (CI): 1.34–5.18) and overall survival (OS) (HR: 2.39, 95%CI: 1.28–4.46). Two gene-body CpG sites (cg10554436 and cg23637494) were moderately and positively correlated with FOXL2 expression. DNA amplification (+2/+1) was common (82/115, 71%) in LSCC, and FOXL2 expression was significantly upregulated in the high-amplification group (+2) compared with copy-neutral (0) cases. Conclusion Aberrant FOXL2 expression may be a novel prognostic biomarker for PFS and OS among patients with LSCC. FOXL2 upregulation may be related to gene-body hypermethylation and DNA amplification.


2012 ◽  
Vol 23 ◽  
pp. ix338-ix339
Author(s):  
D. Dionysopoulos ◽  
K. Pavlakis ◽  
V. Kotoula ◽  
E. Fountzilas ◽  
K. Markou ◽  
...  

Author(s):  
Elizabeth Mathew Iype ◽  
Rajan Balakrishna ◽  
Lakshmi Subhadradevi ◽  
Jissa Vinoda Thulaseedharan ◽  
Bharath Veerabadhran ◽  
...  

<p class="abstract"><strong>Background:</strong> The study was done with the objective to study the expression of epidermal growth factor receptor (EGFR), cyclin D1 and Ki-67 in laryngeal squamous cell carcinoma and to assess the correlation of all three proliferation markers with various clinic-pathological parameters, the treatment outcomes as well as survival.</p><p class="abstract"><strong>Methods:</strong> We prospectively evaluated the surgical specimens of 72 laryngeal squamous cell carcinoma (LSCC) patients, treated with primary surgery and post-operative adjuvant therapy. Tumor tissue samples were analysed for the expression of EGFR, cyclin D1 and Ki-67 markers and analysis were done by immune-histochemistry and western blot test.  </p><p class="abstract"><strong>Results:</strong> EGFR showed significant expression in 67.6% and was insignificant in 31.9% patients in our analysis of 72 tumor samples. Cyclin D1 showed intense expression in 43%, and was insignificant in 57% patients. Ki-67 was intensely expressed in 43% patients. There was no correlation between expression of these markers with age, T-stage and N-stage. However, all the three markers showed significantly intense expression in tumours with extra capsular disease as well as perineural invasion (PNI) both of which are features of invasiveness of the tumor.</p><p class="abstract"><strong>Conclusions:</strong> Estimation of biomarkers such as EGFR, cyclin Dl, and Ki-67 could be beneficial in predicting tumor aggressiveness, prognosis and survival in LSCC patients. Thus, all the three proliferation markers can be categorized as markers of invasiveness. Combination of proliferation markers-EGFR, cyclin D1 and Ki-67 is useful pre-operatively in planning surgical strategies so as to decide a more radical approach for the resection of the primary as well as neck dissection.</p>


Sign in / Sign up

Export Citation Format

Share Document